TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma

Although the development of mitogen-activated protein kinase (MAPK) inhibitors has greatly improved the prognosis of BRAF(V600) cutaneous melanomas, the identification of molecular indicators for mutated patients at risk of early progression remains a major issue. Using an amplicon-based next-genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Blateau, Pauline, Coyaud, Etienne, Laurent, Estelle, Béganton, Benoit, Ducros, Vincent, Chauchard, Géraldine, Vendrell, Julie A., Solassol, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463448/
https://www.ncbi.nlm.nih.gov/pubmed/32784823
http://dx.doi.org/10.3390/cancers12082224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463448/
https://www.ncbi.nlm.nih.gov/pubmed/32784823
http://dx.doi.org/10.3390/cancers12082224

Ejemplares similares